The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy

The CD38 antigen is expressed in several hematological malignancies, and the anti-CD38 monoclonal antibodies Daratumumab and Isatuximab have an established role in the therapy of multiple myeloma. However, data on the therapeutic utility of CD38 targeting in other lymphoid malignancies are limited....

Descripción completa

Detalles Bibliográficos
Autores principales: Calabretta, Eleonora, Carlo-Stella, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226059/
https://www.ncbi.nlm.nih.gov/pubmed/32225002
http://dx.doi.org/10.3390/cells9040802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226059/
https://www.ncbi.nlm.nih.gov/pubmed/32225002
http://dx.doi.org/10.3390/cells9040802

Ejemplares similares